These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17486433)

  • 21. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
    Weintraub D; Somogyi M; Meng X
    Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
    Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG
    Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
    Nordström P; Religa D; Wimo A; Winblad B; Eriksdotter M
    Eur Heart J; 2013 Sep; 34(33):2585-91. PubMed ID: 23735859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging treatment effects in Alzheimer's disease.
    Venneri A
    Magn Reson Imaging; 2007 Jul; 25(6):953-68. PubMed ID: 17446028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease.
    Tang XC
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):481-4. PubMed ID: 9863136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's drugs deliver fringe benefits. Cholinesterase inhibitors improve more than just memory.
    Auerbach SH
    Health News; 2003 Mar; 9(3):1-2. PubMed ID: 12703432
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of drugs for Alzheimer's disease.
    Sun X; Jin L; Ling P
    Drug Discov Ther; 2012 Dec; 6(6):285-90. PubMed ID: 23337815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs for treatment of Alzheimer's disease.
    Wilkinson D
    Int J Clin Pract; 2001 Mar; 55(2):129-34. PubMed ID: 11321852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
    Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Struggling over subjectivity: debates about the "self" and Alzheimer's disease.
    Herskovits E
    Med Anthropol Q; 1995 Jun; 9(2):146-64. PubMed ID: 7671112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease.
    Lin HQ; Ho MT; Lau LS; Wong KK; Shaw PC; Wan DC
    Chem Biol Interact; 2008 Sep; 175(1-3):352-4. PubMed ID: 18573242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches.
    Hake AM
    Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
    Doody RS
    J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why as a medicinal chemist I am not optimistic about the possibility of finding, in a reasonable timeframe, small-molecule drugs capable of curing the evolution of Alzheimer's disease.
    Kraus JL
    ChemMedChem; 2012 Mar; 7(3):357-8. PubMed ID: 21990179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey.
    Natarajan S; Shunmugiah KP; Kasi PD
    Pharm Biol; 2013 Apr; 51(4):492-523. PubMed ID: 23336528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.